Edition:
United States

MDxHealth SA (MDXH.BR)

MDXH.BR on Brussels Stock Exchange

3.69EUR
18 Dec 2017
Change (% chg)

€-0.00 (-0.14%)
Prev Close
€3.69
Open
€3.70
Day's High
€3.70
Day's Low
€3.64
Volume
77,368
Avg. Vol
120,193
52-wk High
€5.78
52-wk Low
€3.63

Latest Key Developments (Source: Significant Developments)

MDxHealth teams up with Ferrer for distribution of its prostate cancer test SelectMDx in Spain
Monday, 20 Nov 2017 01:30am EST 

Nov 20 (Reuters) - MDXHEALTH SA : :REG-MDXHEALTH TEAMS UP WITH PHARMACEUTICAL COMPANY FERRER FOR DISTRIBUTION OF ITS PROSTATE CANCER TEST SELECTMDX IN SPAIN.‍UNDER TERMS OF THIS FIVE-YEAR EXCLUSIVE AGREEMENT, A TEAM OF 10 REPS FROM FERRER'S SALES FORCE OF ARE GOING TO SELL SELECTMDX TEST DIRECTLY TO 1000 UROLOGISTS IN SPAIN​.  Full Article

MDxHealth 9M total revenue at 30.5 million dollars
Thursday, 2 Nov 2017 02:00am EDT 

Nov 2 (Reuters) - MDXHEALTH SA :9M (NOT Q3) NET LOSS $‍​7.4 MILLION VERSUS LOSS OF $10.3 MILLION YEAR AGO.CASH AND CASH EQUIVALENTS ON SEPTEMBER 30, 2017 OF $22.9 MILLION.9M TOTAL REVENUE OF $30.5 MLN‍​.9M EBITDA IMPROVED BY 34.1% FROM $-6.2 MILLION COMPARED TO $-9.1 MILLION IN 2016‍​.TARGETS LOWER END OF ITS 55%-75% PRODUCT AND SERVICE REVENUE GROWTH GUIDANCE FOR 2017.2017 TOTAL REVENUE IS EXPECTED TO GROW BY APPROXIMATELY 60%-70%, TO $48-$51 MILLION.EXPECTS TO MAINTAIN A BALANCE OF CASH AND CASH EQUIVALENTS OF APPROXIMATELY $15 MILLION AT THE END OF 2017.  Full Article

MDxhealth enters distribution agreement with Unilabs for SelectMDx
Monday, 30 Oct 2017 02:00am EDT 

Oct 30 (Reuters) - MDXHEALTH SA ::‍MDXHEALTH ENTERS INTO DISTRIBUTION AGREEMENT WITH UNILABS FOR SELECTMDX FOR PROSTATE CANCER.​.  Full Article

MDxHealth appoints Michael K. Brawer as Chief Medical Officer‍​
Wednesday, 6 Sep 2017 01:00am EDT 

Sept 6 (Reuters) - MDXHEALTH SA ::ANNOUNCES APPOINTMENT OF MICHAEL K. BRAWER, MD AS CHIEF MEDICAL OFFICER‍​.  Full Article

MDxHealth H1 EBITDA rises to 1.4 million dollars
Thursday, 31 Aug 2017 01:30am EDT 

Aug 31 (Reuters) - MDXHEALTH SA ::H1 ‍TOTAL REVENUE OF $24.3 MILLION, UP 87% FROM $12.9 MILLION IN 2016​.H1 ‍PRODUCT REVENUE WAS $12 MILLION, UP 10% FROM $10.9 MILLION;​.H1 ‍OPERATING PROFIT OF $0.6 MILLION COMPARED TO AN OPERATING LOSS OF $7.5 MILLION YEAR AGO​.‍FOR 2017 MAINTAINS ITS PRODUCT AND SERVICE REVENUE GUIDANCE OF GROWTH BETWEEN 55% TO 75%, EXCLUDING ROYALTIES AND MILESTONE PAYMENTS​.H1 EBITDA $1.4 MILLION VERSUS LOSS OF $6.7 MILLION YEAR AGO.H1 NET INCOME $538,000 VERSUS LOSS OF $7.6 MILLION YEAR AGO.  Full Article

MDxHealth announces results identifying lack of knowledge on new generation biomarker tests for prostate cancer
Monday, 3 Jul 2017 01:14am EDT 

July 3 (Reuters) - MDXHEALTH SA ::ANNOUNCES RESULTS FROM AN INDEPENDENT SURVEY IDENTIFY LACK OF KNOWLEDGE ON NEW GENERATION BIOMARKER TESTS FOR PROSTATE CANCER.  Full Article

MdxHealth Q1 revenue growth of 128%, or $19.4 million
Monday, 8 May 2017 01:01am EDT 

May 8 (Reuters) - MDXHEALTH SA ::Q1 SHARP REVENUE GROWTH OF 128%, OR $19.4 MILLION, COMPARED TO THE SAME PERIOD IN 2016.CASH AND CASH EQUIVALENTS ON APRIL 30 2017 OF $35.1 MILLION.THE COMPANY MAINTAINS ITS GUIDANCE FOR THE 2017 FISCAL YEAR.FOR 2017: GROWTH BETWEEN 55% TO 75% ON PRODUCT AND SERVICE INCOME.  Full Article

MDxHealth and Maastricht University collaborate on (EPI)genetic cancer diagnostics
Friday, 5 May 2017 01:00am EDT 

May 5 (Reuters) - MDxHealth SA ::Mdxhealth and maastricht university collaborate on next generation (EPI)genetic cancer diagnostics.Under the terms of the multi-year research and development agreement, the collaboration will focus on developing (EPI)genetic-based assays to provide better insight in the diagnosis, staging and treatment of cancer patients.  Full Article

Mdxhealth and Exact Sciences sign collaboration agreement
Thursday, 27 Apr 2017 01:00am EDT 

April 27 (Reuters) - Mdxhealth Sa : :Mdxhealth and Exact Sciences sign collaboration agreement for collaboration in the growing field of epigenetics and molecular diagnostics.These acquisitions include one-time fees totaling $15 million, including payments accrued since July 2016.Exact Sciences is also acquiring Mdxhealth patents directed toward colorectal cancer.  Full Article

Mdxhealth signs an exclusive licensing deal with Ghent University in Belgium
Tuesday, 4 Apr 2017 01:01am EDT 

Mdxhealth SA : Signed an exclusive licensing deal with Ghent University in Belgium . The collaboration agreements aim to develop cancer biomarker visualization technology .Has also joined forces with University to leverage licensed technology for company's current and future in vitro diagnostic (IVD) kits and laboratory developed tests (LDTs).  Full Article

BRIEF-MDxHealth teams up with Ferrer for distribution of its prostate cancer test SelectMDx in Spain

* REG-MDXHEALTH TEAMS UP WITH PHARMACEUTICAL COMPANY FERRER FOR DISTRIBUTION OF ITS PROSTATE CANCER TEST SELECTMDX IN SPAIN